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Abstract
Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an aberrant inflammatory
response occurring in a subset of TB-HIV co-infected patients initiating anti-retroviral therapy (ART). Here, we examined
monocyte activation by prospectively quantitating pro-inflammatory plasma markers and monocyte subsets in TB-HIV co-
infected patients from a South Indian cohort at baseline and following ART initiation at the time of IRIS, or at equivalent
time points in non-IRIS controls. Pro-inflammatory biomarkers of innate and myeloid cell activation were increased in
plasma of IRIS patients pre-ART and at the time of IRIS; this association was confirmed in a second cohort in South Africa.
Increased expression of these markers correlated with elevated antigen load as measured by higher sputum culture grade
and shorter duration of anti-TB therapy. Phenotypic analysis revealed the frequency of CD14++CD162 monocytes was an
independent predictor of TB-IRIS, and was closely associated with plasma levels of CRP, TNF, IL-6 and tissue factor during
IRIS. In addition, production of inflammatory cytokines by monocytes was higher in IRIS patients compared to controls pre-
ART. These data point to a major role of mycobacterial antigen load and myeloid cell hyperactivation in the pathogenesis of
TB-IRIS, and implicate monocytes and monocyte-derived cytokines as potential targets for TB-IRIS prevention or treatment.
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Introduction
Implementation of antiretroviral therapy (ART) in patients co-
infected with HIV and tuberculosis (TB) has greatly improved life
expectancy [1–5]. Anti-retroviral therapy reconstitutes the number
and function of CD4+ T-cells and most patients manifest clinical
improvement of signs and symptoms of opportunistic co-infections
including tuberculosis (TB). Nevertheless, some patients experience
a paradoxical worsening of TB during the first 3 months of ART, a
phenomenon known as immune reconstitution inflammatory
syndrome or IRIS [6–8]. The incidence of TB-IRIS is variable
(from 8 to 54%) depending on the epidemiological settings [9–14].
The clinical manifestations can range from fever and lymph node
enlargement to sepsis-like syndrome and neurological deterioration
[7]. The immunological basis of the pathological mechanisms
leading to TB-IRIS is still not fully understood. The clinical onset of
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IRIS has been linked to hyperactivation of T-cells specific for antigens
from opportunistic pathogens, resulting in an inflammatory cytokine
storm [15–20]. In addition, different components of the innate
immune response such as natural killer cells (NK) [21], macrophages
[22], monocytes [23,24] and neutrophils [25] have been implicated in
the pathogenesis of TB-IRIS [26]. Monocytes are critical for host
immunity against both TB and HIV, and as such, their specific role in
TB-IRIS warrants better understanding. In a recent study of TB-
IRIS, transcriptional analysis of monocytes suggested a potential role
of monocytes and the complement system in this phenomenon [24].
In addition, myeloid cells and innate cytokines such as IL-6 have been
proposed to play a role in mycobacterial IRIS, as suggested in an
animal model of IRIS developed by our group [27,28].
Human monocyte subpopulations can be categorized based on
the dichotomous expression of the surface markers CD14 and
CD16 into three major subsets: CD14++CD162, CD14+CD16+
and CD14dimCD16+. These different monocyte subsets have been
described to exhibit very distinct functional roles in a range of
homeostatic and pathological conditions [29]. No detailed analysis
of the different monocyte subsets in TB-IRIS has been performed
in patients. The goal of the present study was to evaluate the role
of monocyte subsets and their association with pro-inflammatory
cytokines in the setting of TB-IRIS. Our findings from studying
three geographically distinct patient cohorts demonstrate that
expansion and activation of the CD14++CD162 monocyte subset
is closely associated with the pathogenesis of TB-IRIS.
Results
Paradoxical TB-IRIS is characterized by high plasma levels
of inflammatory biomarkers related to monocytes
TB-IRIS has been clearly shown to be associated with elevated
plasma concentrations of several pro-inflammatory and
anti-inflammatory cytokines [20], some of them known to be
strongly linked to monocyte stimulation. We tested whether the
monocyte and macrophage activation markers sCD14, sCD163
and sTF were also altered in TB-IRIS in a cohort of patients from
South India. We found significantly higher levels in TB-IRIS
patients vs. non-IRIS controls at baseline of sCD163 (median
3638 ng/mL, IQR: 3411–3880 ng/mL vs. 3257 ng/mL, IQR:
2823–3343 ng/mL, P,0.001) and sTF (median 32.5 pg/mL,
IQR: 19.3–52.1 pg/mL vs. 13.9 pg/mL, IQR: 10.2–28.2 pg/mL,
P,0.001), whereas sCD14 was significantly lower at baseline
(median 3.8 mg/mL, IQR: 3.2–4.4 mg/mL vs. 5.5 mg/mL, IQR:
4.4–6.7 mg/mL, P,0.001). At the time of IRIS, levels of all three
markers were higher in IRIS patients compared to non-IRIS
controls (Figure 1). In addition, statistically significant differences
were observed when comparing changes from baseline to the time
of IRIS or an equivalent time point in the IRIS vs. non-IRIS
groups for sCD14 (median fold-change from baseline 1.2, IQR:
0.64–1.7 vs. 0.6, IQR: 0.45–0.9, P = 0.012), sCD163 (median fold-
change from baseline 1.0, IQR: 0.94–1.1 vs. 0.94, IQR: 0.85–1.0,
P = 0.015) and sTF (median fold-change from baseline 2.4, IQR:
2.1–2.9 vs. 1.07, IQR: 0.76–2.5, P,0.001). At 24 weeks after ART
initiation, levels of these biomarkers significantly decreased in both
IRIS and non-IRIS patients, with no significant differences
between the groups except for sCD163 levels, which remained
higher in the IRIS group (Figure 1A–C).
We next compared plasma levels of several pro- and anti-
inflammatory cytokines, chemokines and markers of tissue
damage in the Indian cohort. Consistent with previous reports
[20], we confirmed that after ART initiation, patients who
experienced IRIS exhibited elevated levels of many pro- and
anti-inflammatory biomarkers with 7 out of the 16 cytokines and
chemokines measured dramatically elevated in TB-IRIS pa-
tients (Figure 1D and Table S1). Nevertheless, circulating levels
of CXCL10, IL-12p70 and PDGF were higher in non-IRIS
control patients (Figure 1D and Table S1). In addition, after 6
weeks of ART, individuals without IRIS events had higher
plasma concentrations of I-FABP and CCL5 (Figure 1D and
Table S1).
As reported in other studies, a critical difference between the
patients who developed IRIS and those who did not was
duration of anti-TB therapy (ATT) before ART initiation at
study baseline: median of 20 days (IQR: 14–30 days) in TB-
IRIS cases versus 43 days (IQR: 23–68 days) in controls
(P = 0.002) [30]. In order to assess how the duration of ATT
impacts the cytokine and chemokine profile of patients prior to
ART (a factor that has been repeatedly associated with risk of
IRIS), we compared the concentrations of plasma biomarkers in
study patients grouped according to time on ATT (Figure 2). As
expected, the mycobacterial load in sputum cultures significant-
ly reduced with time on ATT (P = 0.005; Figure 2A). The
pattern of distribution of plasma biomarkers also changed
significantly with duration of ATT. Individuals who were on
ATT for less than 4 weeks exhibited higher concentrations of
plasma biomarkers associated with activation of innate immune
responses, such as IL-1b, IL-6, CRP, sCD163, IL-8, CCL2,
PDGF as well as several chemokines (Figure 2B). In contrast,
biomarkers that are more closely associated with activation of
adaptive immune responses, such as IFN-c, IL-2, IL-15, sPD-1
and IL-7, were higher in patients who were on ATT for more
than 4 weeks before ART initiation. The finding that IRIS
patients received ATT for a shorter time before ART initiation
(Figure 2A) suggested the importance of an elevated Mtb
antigen load, as supported by increased colony forming unit
grades in sputum Mtb cultures.
Author Summary
Tuberculosis and HIV majorly impact host immune
responses, resulting in immune deregulation and inflam-
mation-driven tissue damage. Initiation of anti-retroviral
therapy in patients with HIV-TB co-infection may result in
immune reconstitution inflammatory syndrome (TB-IRIS), a
disorder associated with increased immunopathology due
to unfettered inflammation after CD4+ T-cell reconstitu-
tion. Monocytes are critical to the innate immune system
and play an important role in several inflammatory
conditions associated with chronic infections. Immuno-
pathogenesis of TB-IRIS has been linked to activation of
the adaptive immune response against opportunistic
infection, yet the role of monocytes is still unknown. Here
we investigated associations between soluble markers of
monocyte activation, differential activation of monocyte
subsets and TB-IRIS prospectively in two geographically
distinct HIV-TB co-infected patient cohorts. Prior to ART
initiation, patients who developed IRIS displayed a
biosignature of elevated soluble monocyte activation
markers, which were closely related to the mycobacterial
antigen load in sputum samples. Amongst monocyte
subsets, we observed that pre-ART circulating
CD14++CD162 cell frequency independently predicted
TB-IRIS and expanded during IRIS events. This monocyte
subset was tightly associated with systemic markers of
inflammation, and was found to produce inflammatory
cytokines. Identification of this monocyte subset and its
link with inflammation may lead to conception of novel
therapies reducing immunopathology in TB-IRIS.
Activated Inflammatory Monocytes in TB-IRIS
PLOS Pathogens | www.plospathogens.org 2 October 2014 | Volume 10 | Issue 10 | e1004433
Figure 1. Plasma concentrations of monocyte activation markers are increased during TB-IRIS and correlate with markers of
systemic inflammation. (A–C) Plasma levels of soluble (s) CD14 (A), sCD163 (B) and sTF (C) are compared at week 0 (pre-ART), at week 6 or at the
time of IRIS, and at week 24 after ART initiation between TB-HIV co-infected patients who developed paradoxical TB-IRIS (n = 26) and those who did
not (n = 22). Lines represent median values and interquartile ranges. Data were analyzed using Mann-Whitney or Wilcoxon matched-pairs test for
paired analyses within each study group. * P,0.05, ** P,0.01, *** P,0.001. (D) Left panel: A heat map was designed to depict the overall pattern of
expression of plasma cytokines, chemokines and inflammatory markers in patients developing TB-IRIS vs. non-IRIS controls at week 0 (pre-ART) and at
week 6 or during the time of IRIS. A two-way hierarchical cluster analysis (Ward’s method) of circulating biomarkers by clinical group and time point
was performed. Expression scale for each biomarker represents log10 fold-change from the geometric mean of the entire study population at week 0
and week 6 or time of IRIS (n = 48 in each study time point). Right panel: The network analysis (interactome) shows statistically significant correlations
(P,0.05) between all the variables measured. Data were analyzed using Spearman rank tests. See Data File S1 for additional details on the strength (r
value) and level of significance (P-value) of each individual correlation.
doi:10.1371/journal.ppat.1004433.g001
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The plasma inflammatory profile of TB-IRIS patients is not
associated with absolute counts of monocytes or
neutrophils in the peripheral blood
To further investigate the association between monocyte
activation markers and systemic inflammation in TB-IRIS, we
employed a network analysis based on multiple Spearman
correlations between all the biomarkers measured in plasma
(Figure 1D and Data File S1). We found that in IRIS patients, the
number of significant correlations between multiple variables was
very high compared to non-IRIS controls (P,0.001; Figure 1D,
Data File S1 and Figure S2). This finding from network analysis
argues that the cytokine storm observed in TB-IRIS is tightly
coordinated. In addition, the direction of change in network
densities observed in the IRIS vs. non-IRIS groups did not seem to
be associated with HIV viral load or CD4+ T-cell count (Figure
S2), implying that other factors may affect more directly how
plasma biomarkers correlate with one another.
Our results from measurements of multiple plasma biomarkers
suggest that biomarkers of monocyte activation are associated with
the inflammatory environment of TB-IRIS after ART initiation.
We next tested whether the concentration of monocytes in
peripheral blood reflected the observations from plasma protein
analysis and found no significant differences in total monocyte
counts between the study groups at the different time points
evaluated (Figure 3A). Absolute neutrophil counts were higher in
the IRIS group at week 6 compared to non-IRIS controls (P,
0.001; Figure 3A). However, the network analysis revealed a lack
of significant correlations between absolute neutrophil and
monocyte counts and the plasma biomarkers of inflammation at
all time points studied (Figure 3B). At enrollment (pre-ART),
patients who developed IRIS during the study displayed significant
positive correlations between monocyte counts and innate
cytokines such as IL-1b (r = 0.53, P = 0.012), IL-6 (r = 0.67,
P = 0.001) and IL-8 (r = 0.49, P = 0.023) (Figure 3B).
To test whether the findings from our Indian cohort could be
validated in another area endemic for TB-HIV co-infection, we
performed similar analyses of plasma biomarkers and absolute cell
counts in a cohort of HIV-TB co-infected patients from South
Africa, which has been previously described [31,32]. Levels of
sCD14 were not significantly different between the groups at
Figure 2. Expression profile of plasma biomarkers of inflammation and immune activation in TB-HIV co-infected patients on anti-
TB therapy. (A) Left panel shows Mycobacterium tuberculosis sputum culture grade in samples from TB-HIV co-infected individuals at study
enrollment (pre-ART) stratified by time on anti-TB treatment (ATT). Data were compared using the Mann-Whitney test. Right panel shows the
frequency of IRIS vs. non-IRIS patients taking ATT for different durations (#4 weeks and.4 weeks). Data were compared using the Chi-square test. (B)
A heat map was designed to depict the overall pattern of expression of plasma cytokines, chemokines and inflammatory biomarkers in TB-HIV co-
infected patients at different time points after ATT initiation. A hierarchical cluster analysis (Ward’s method) of circulating biomarkers by clinical group
and time point was performed. Expression scale for each biomarker represents change from the geometric mean of the entire study population
(n = 48). Differences between medians were compared using the Mann-Whitney test. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.ppat.1004433.g002
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Figure 3. Circulating monocyte counts do not correlate with soluble biomarkers of inflammation and immune activation in TB-HIV
co-infected individuals. (A) Numbers of circulating monocytes (left panel) and neutrophils (right panel) are compared at week 0 (pre-ART), at
weeks 6 or at the time of IRIS, and at week 24 after ART initiation between TB-HIV co-infected patients who developed paradoxical TB-IRIS (n = 26)
and those who did not (n = 22). Lines represent median values and interquartile ranges. Data were analyzed using the Mann-Whitney test or Wilcoxon
matched-pairs test for paired comparisons within each study group. ** P,0.01, *** P,0.001. (B) The network analysis (interactome) showed
statistically significant correlations (P,0.05) between neutrophil or monocyte counts and plasma biomarkers. Associations were assessed with
Spearman rank tests.
doi:10.1371/journal.ppat.1004433.g003
Activated Inflammatory Monocytes in TB-IRIS
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baseline (pre-ART) (P = 0.502) and similarly to what was observed
in the South Indian cohort, the values were significantly higher at
week 2 in the IRIS group (P = 0.003; Figure 4A and Table S2).
Levels of sCD163 were again higher before ART initiation in
patients who developed IRIS compared to those who did not
(median 1947 ng/mL, IQR: 1543–2582 ng/mL vs. 1612 ng/mL,
IQR: 1473–1692 ng/mL, P = 0.001) and remained elevated at the
time of IRIS without a significant change from baseline
(Figure 4B). Pre-ART plasma levels of sTF did not differ
(14.5 pg/mL, IQR: 7.7–24.7 pg/mL vs. 13.9 pg/mL, IQR: 3.6–
28.9 pg/mL, P = 0.078), but were increased upon ART initiation
in IRIS patients, whereas they did not change in non-IRIS
patients (median fold-change from baseline 1.25, IQR: 0.89–1.63
vs. 0.69, IQR: 0.47–1.02, P = 0.036, Figure 4B). Monocyte counts
remained unchanged upon ART initiation in both groups
(Figure 4C), whereas absolute neutrophil counts were higher
during the IRIS event in the IRIS group (median 5161 cells/mL,
IQR: 3590–6460 cells/mL vs. 3375 cells/mL, IQR: 2065–6595
cells/mL, P = 0.018, Figure 4D). In addition, further analysis using
measurements of all the biomarkers available in the South African
cohort validated the following findings from the Indian cohort: (i)
plasma concentrations of most of the inflammatory biomarkers
were increased during the time of IRIS (Figure 4, Table S2); (ii)
the number of statistically significant correlations was greatly
increased during the time of IRIS compared to matched time
points in non-IRIS patients, as revealed by network analysis (P,
0.001; Figure 4E, Figure S2 and Data File S2); and (iii) there was a
lack of significant correlations between absolute neutrophil and
monocyte counts and plasma biomarkers (Figure 4E).
Expansion of circulating CD14++CD162 monocytes with
high expression of CD163 and lack of CD14dimCD16+ cells
in TB-IRIS
Our results from two separate areas endemic for HIV-TB co-
infection suggest that soluble markers of monocyte/myeloid
activation are associated with the occurrence of paradoxical TB-
IRIS following ART initiation, but total monocyte or neutrophil
counts do not seem to influence this association. We then
hypothesized, that differences in monocyte subsets rather than
total monocyte counts could explain the results from plasma
analyses. To address this, we performed multicolor flow cytometry
experiments in whole blood for phenotypic analysis of monocyte
subsets from patients in the Indian cohort (Figure S1). At study
baseline and also after ART initiation, individuals who developed
IRIS exhibited higher frequencies vs. non-IRIS patients of
CD14++CD162 (median 73.2% of circulating mononuclear
myeloid cells, IQR: 64.7–75.1% vs. 65.6%, IQR: 60.9–68.8%,
P = 0.029) and CD14+CD16+ (median 10.4% of circulating
mononuclear myeloid cells, IQR: 7.2–14.5% vs. 7.6%, IQR:
6.2–8.6%, P = 0.008) monocyte subsets, whereas the
CD14dimCD16+ monocyte subset was significantly decreased
(median 3.9% of circulating mononuclear myeloid cells, IQR:
3.1–5.8% vs. 18.9%, IQR: 12.6–22.7%, P,0.001) (Figure 5A–B).
Analyses of the monocyte subsets confirmed that the chemokine
receptor CX3CR1 was more highly expressed in the
CD14dimCD16+ subset, whereas CCR2 was more prevalent in
the CD14++CD162 and CD14+CD16+ subsets (Figure 5A). The
CD14dimCD16+ subset also displayed slightly reduced (albeit not
significantly different) expression of HLA-DR and CCR5 com-
pared with other monocyte subsets at the time of IRIS event, as
assessed by mean fluorescence intensity (MFI) (Figure 5A). Among
the surface markers evaluated, CD163 displayed marked variation
in expression, especially in the CD14++CD162 subset (Figure 5A–
D). CD163 expression co-localized with CD14 on the surface of
monocytes (Figure 5C) and was elevated pre-ART on
CD14++CD162 monocytes in IRIS patients compared with non-
IRIS controls (MFI 1271 arbitrary units [AU], IQR: 100.1–3696
AU vs. 101.5 AU, IQR: 47.5–425.0 AU, P = 0.002; Figure 5D),
being further increased at the time of IRIS (MFI 5000.3 AU, IQR:
1000.5–20050.6 AU at IRIS event vs. 146.0 AU, IQR: 20.3–492.5
AU at week 6 in non-IRIS controls, P,0.001; Figure 5D).
Moreover, CD163 expression on the CD14++CD162 subset was
positively correlated with plasma levels of sCD163 (Spearman
r = 0.63, P,0.001), suggesting that this monocyte subset could be
a source of the soluble receptor.
We next analyzed the changes in each of the major monocyte
and other mononuclear myeloid subsets between study baseline
and the time of IRIS or 6 weeks post-ART initiation in non-IRIS
patients. The total number of circulating mononuclear myeloid
cells did not significantly change in IRIS (34.7612.5% of total
PBMC) or non-IRIS patients (35.269.3% of total PBMC) (Figure
S3A). Among all monocytes, the CD14++CD162 subset exhibited
the greatest increase in IRIS patients and the greatest decrease in
non-IRIS patients after ART initiation (median delta variation for
IRIS vs. non-IRIS groups: 9.9%, IQR: 8.5 to 11.5% vs. 27.7%,
IQR: 25.7 to 28.2%, P,0.001; Figure S3B). Multivariate logistic
regression analysis adjusted for baseline age, gender, days to ART
initiation, plasma HIV RNA levels and CD4+ T-cell count
revealed that the frequency of each circulating monocyte subset
prior to ART initiation was an independent predictor of TB-IRIS
developing during the study (Figure 5E).
These results support the idea that monocyte subsets are
associated with the occurrence of TB-IRIS in HIV patients
following ART initiation and, specifically, that circulating
CD14++CD162 cells are associated with IRIS pathogenesis. This
was further supported by the fact that, in the entire Indian cohort
(n = 48), the frequency of circulating CD14++CD162 monocytes,
but not other subsets, was strongly correlated with several key
cytokines associated with inflammation and IRIS both at baseline
(pre-ART) and after ART initiation (Figure 6).
Our results have demonstrated that CD14++CD162 monocytes
expand in the blood after ART initiation in patients who develop TB-
IRIS (Figure 5 and Figure S3) and also correlate with the
inflammatory milieu seen during the IRIS episode (Figure 6). We
have also shown that the patients receiving ATT for shorter periods
before ART initiation exhibited heightened Mtb sputum culture
grades (suggestive of elevated mycobacterial burden) and displayed
increased plasma concentration of several inflammatory cytokines
associated with IRIS (Figure 2). These observations indicate that the
mycobacterial load prior to immune reconstitution with ART may be
critical to promote the inflammatory environment of IRIS. We
hypothesized that elevated mycobacterial load leads to increased
production of pro-inflammatory cytokines by monocytes in HIV
infected patients responding to ART (after HIV viremia suppression).
To test this hypothesis, we assessed the intracellular cytokine
production by monocytes in North American HIV infected patients
at pre-ART and week 8 post-ART initiation, who were not co-
infected with Mtb (to control for differences of in vivo exposure to
mycobacteria). We observed that the CD14++CD162 monocyte
subset represented the vast majority of IL-6 and TNF-a producing
monocytes after Mtb stimulation (Figure 7A). Monocytes from HIV+
patients with suppressed viral load produced more intracellular IL-6
and TNF-a spontaneously and also upon stimulation with different
doses of Mtb than those from individuals with HIV viremia
(Figure 7B). These results argue that once HIV viral load is suppressed
and CD4 cell numbers increase shortly after ART initiation,
inflammatory monocytes can respond to Mtb with augmented
production of IL-6 and TNF-a, cytokines tightly associated with IRIS.
Activated Inflammatory Monocytes in TB-IRIS
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Next, we directly tested if, aside from being strong predictors of
IRIS, the CD14++CD162 monocytes can produce key cytokines
such as IL-1b, IL-6 and/or TNF-a in TB-IRIS patients. We
performed intracellular cytokine assays in whole blood samples
available from our South India Cohort (17 individuals who
developed IRIS and 15 patients from the non-IRIS group).
Monocytes, but not neutrophils, had high production of IL-1b, IL-
6 and/or TNF-a when directly tested ex vitro (Figure 8A and
Figure S4). Consistent with our observed associations, the cytokine
producing monocytes seemed to be restricted within the
CD14++CD162 subset (Figure S4). Before ART initiation, IRIS
patients exhibited an increased frequency of monocytes producing
at least one of these pro-inflammatory cytokines than non-IRIS
individuals (Figure 8B). At week 6 or IRIS event, there was no
significant difference in the frequency of monocytes producing IL-
1b, IL-6 and/or TNF-a (Figure 8B) although patients developing
an IRIS event exhibited considerably increased frequency of total
IL-1b and IL-6 producing cells, but not TNF-a, compared to non-
IRIS patients. The increased frequency of monocytes producing
pro-inflammatory cytokines prior to ART initiation was also
strongly associated with a reduced time on ATT (#4 weeks) and
increased Mtb loads in sputum cultures (Figure 8C). These
findings reinforce previous results associating higher pre-ART
mycobacterial loads in IRIS patients [33] and strongly suggest that
mycobacterial antigen load-driven monocyte activation contrib-
utes to systemic inflammation that predisposes to TB-IRIS.
Figure 4. TB-HIV co-infected patients from South Africa exhibited a similar inflammatory biomarker pattern of paradoxical TB-IRIS
as well as a lack of correlation between monocyte counts and soluble biomarkers of inflammation. (A–D) Plasma levels of sCD14 (A),
sCD163 (B), sTF (C), absolute monocyte count (D), and absolute neutrophil counts (E) were compared at week 0 (pre-ART) and at week 2 after ART
initiation between TB-HIV co-infected patients that developed paradoxical TB-IRIS (n = 44) and those who did not (n = 52). Lines represent median
values and interquartile ranges. Data were analyzed using the Mann-Whitney test or Wilcoxon matched-pairs test for paired comparisons within each
study group. * P,0.05, ** P,0.01. (F) Left panel: A Heat map was designed to depict the overall pattern of expression of plasma cytokines,
chemokines and inflammatory biomarkers in IRIS vs. non-IRIS patients at week 0 (pre-ART) and at week 2. A two-way hierarchical cluster analysis
(Ward’s method) of circulating biomarkers by clinical group and time point was performed. Expression scale for each biomarker represents log10 fold-
change from the geometric mean of the entire study population at week 0 and week 2 or the time of IRIS (n = 96 at each study time point). Right
panel: The network analysis (interactome) shows statistically significant correlations (P,0.05) between all the parameters measured. Data were
analyzed using Spearman rank tests. See Data File S2 for additional details on the strength (r value) and level of significance (P-value) of each
individual correlation.
doi:10.1371/journal.ppat.1004433.g004
Activated Inflammatory Monocytes in TB-IRIS
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Figure 5. Dynamics of circulating monocyte subsets in TB-HIV co-infected patients following ART initiation. (A) Left panel:
Representative FACS plots showing the distribution of the monocyte subsets defined by CD14 and CD16 markers at week 0 and at week 6 or time of
IRIS in IRIS vs. non-IRIS patients. Monocytes were also defined according to expression of CCR2 and CX3CR1 and overlaid onto CD14 vs. CD16 graphs.
Right panel: Representative FACS plots showing histograms of various phenotypic markers in monocyte subsets based on CD14 and CD16 expression
Activated Inflammatory Monocytes in TB-IRIS
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Discussion
Monocytes are a key component of the innate immune response
and a critical link between innate and adaptive immunity. Despite
the importance of monocytes in resistance to HIV infection and
tuberculosis [34,35], the role of monocyte subsets in TB-IRIS has
not been systematically investigated. Results from transcriptional
analyses recently suggested potential direct participation of
monocytes in the pathogenesis of TB-IRIS [23,24]. In the present
study, soluble biomarkers of inflammation and monocyte activa-
tion were evaluated in patients with TB-HIV co-infection from
India and South Africa, to examine the role of monocytes in
pathogenesis of TB-IRIS. Our findings revealed distinct differ-
ences in monocyte subsets between individuals who developed
paradoxical TB-IRIS compared to those who did not, which were
strongly linked to the profound inflammatory milieu of IRIS.
Soluble markers derived from monocyte activation, such as
sCD14, sCD163 and sTF have been extensively described in the
context of HIV infection [36–40]. Plasma levels of sCD14 have
been established as a strong indicator of monocyte activation [41]
and as an independent predictor of death [38]. Here, we describe
that pre-ART plasma levels of sCD14 increased at the time of
IRIS, while decreasing in individuals not developing IRIS. In
addition, patients in this study who developed IRIS already
exhibited increased levels of CD163 pre-ART, which were
sustained at high levels for up to 24 weeks after ART initiation.
Levels of sCD163 positively correlated with the degree of cellular
expression of CD163 on CD14++CD162 monocytes, implying that
this subset might be an important source of this marker in TB-
IRIS. Our results showing an association between sCD163 and
IRIS are not surprising, as this marker has been linked to a worse
prognosis and increased HIV activity both prior to and after ART
by clinical group and time point. (B) Percentage of circulating CD14++CD162 (left), CD14+CD16+ (center) and CD14dimCD16+ (right) monocytes among
circulating mononuclear myeloid cells (HLADR+CD22CD32CD192CD202CD562) were compared at week 0 (pre-ART) and at week 6 or at the time of
IRIS after ART initiation between TB-HIV co-infected patients that developed paradoxical TB-IRIS (n = 26) and those who did not (n = 22). Lines
represent median values and interquartile ranges. Data were analyzed using the Mann-Whitney test or Wilcoxon matched-pairs test for paired
analyses within each study group. (C) Representative FACS plots showing co-localization of CD163 and CD14 in circulating monocytes from an IRIS
patient at week 2 of ART. (D) The median fluorescence intensity (MFI) of CD163 expression on CD14++CD162 monocytes is compared at week 0 (pre-
ART) and week 6 or at the time of IRIS after ART initiation between TB-HIV co-infected patients that developed paradoxical TB-IRIS (n = 26) and those
who did not (n = 22) using the Mann-Whitney test. (E) Relative risk (RR) of developing paradoxical TB-IRIS per standard deviation increase in the
frequency of specific monocyte subsets at week 0 (pre-ART) after log10 transformation. RR were adjusted for baseline age, gender, days to ART
initiation, plasma HIV RNA levels and CD4+ T-cell count. CI, confidence interval. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.ppat.1004433.g005
Figure 6. The CD14++CD162 monocyte subset strongly correlates with pro-inflammatory biomarkers in TB-HIV co-infected
individuals upon ART initiation. Percentage of circulating CD14++CD162 (left), CD14+CD16+ (center) and CD14dimCD16+ (right) monocytes
among circulating mononuclear myeloid cells were tested for correlations with several pro-inflammatory cytokines and chemokines at week 0 (pre-
ART) and at week 6 or at the time of IRIS after ART initiation in the entire study population (n = 48). Bars represent the strength of associations (r
values), and P-values of statistically significant results are displayed.
doi:10.1371/journal.ppat.1004433.g006
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Figure 7. Intracellular production of IL-6 and TNF-a by monocytes from HIV+ patients is affected by HIV plasma viremia and
mycobacterial antigen load. Paired PBMC samples from eight HIV-infected individuals prior to ART initiation and after 8 weeks of treatment when
patients achieved virological suppression were incubated in vitro with different doses of irradiated M. tuberculosis (Mtb) for 6 h in the presence of
brefeldin-A. Intracellular cytokine assays for detection of IL-6 and TNF-a in monocytes (HLA-DR+Dump2 cells) were performed by multicolor flow
cytometry. Gates for cytokines were set up based on fluorescent minus one controls. (A) Representative FACS plots of percentage of monocytes
expressing IL-6 or TNF-a (left panels) following stimulation with increasing doses of Mtb. Right panel shows overlays of CD14 vs. CD16 expression on
cytokine-producing cells after stimulation with irradiated Mtb 100 mg/mL and reveals that most of the cytokine-producing cells in this in vitro system
are CD14++CD162 monocytes. (B) Percentage of monocytes from HIV+ patients with high or low viral loads stained positive for intracellular IL-6 after
in vitro stimulation with different doses of irradiated Mtb. Data were analyzed using the Wilcoxon matched pairs test. (C) Percentage of monocytes
from HIV+ patients with high or low viral loads stained positive for intracellular TNF-a after in vitro stimulation with different doses of irradiated Mtb.
Data were analyzed using the Wilcoxon matched pairs test. * P,0.05.
doi:10.1371/journal.ppat.1004433.g007
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initiation [36] and appears to be an independent predictor of
mortality in TB [37].
Activated monocytes in the circulation and tissue macrophages
are also a major source of TF [42]. The shedding of TF by these
cells triggers coagulation, which has been clearly associated with
increased mortality and cardiovascular complications in HIV
infection [39,40]. More recently, it has been shown that Mtb
induces TF expression in macrophages and Mtb signaling
pathways that induce TF require cooperation of multiple receptors
and co-factors including Toll-like receptors [43]. Our results
demonstrate that levels of sTF in plasma are already elevated
before ART initiation and increase even more in patients who
develop IRIS upon immune reconstitution. Increased TF expres-
sion could be one of the factors that, together with sCD163,
influence the onset of IRIS. More importantly, the analysis of
plasma biomarkers of monocyte activation in this study favors the
Figure 8. Increased frequency of monocytes spontaneously producing pro-inflammatory cytokines pre-ART in TB-IRIS patients.
Whole blood intracellular cytokine assay was performed in 17 individuals from the IRIS group and 15 non-IRIS patients from the South Indian cohort.
(A) Gating strategy to assess intracellular cytokine production by neutrophils and monocytes/DCs and (B) frequency of cells producing IL-1b, IL-6
and/or TNF-a after 6 hour in vitro culture in the presence of brefeldin-A (unstimulated). (C) Pre-ART frequency of monocytes producing IL-1b, IL-6
and/or TNF-a was compared between IRIS and non-IRIS patients stratified by time on ATT or M. tuberculosis loads in sputum cultures. Data were
analyzed using Mann-Whitney or Wilcoxon matched-pairs test for paired analyses within each study group. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.ppat.1004433.g008
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idea of increased monocyte activation prior to ART in patients
who ultimately develop TB-IRIS and is corroborated by increased
cytokine production by monocytes pre-ART in TB-IRIS patients.
There is now strong evidence that patients experiencing TB-
IRIS exhibit increased systemic concentrations of multiple
cytokines, chemokines and growth factors, a phenomenon known
as cytokine storm or hypercytokinemia [20]. Our findings assessing
multiple plasma biomarkers from patients originating from two
different endemic countries for HIV-TB co-infection reinforce this
idea. Interestingly, ATT itself seems to considerably affect the
expression of several plasma biomarkers. At less than 4 weeks after
TB treatment initiation, TB-HIV co-infected individuals exhibited
increased concentrations of several plasma factors of innate
immune origin, such as IL-1b, IL-6, IL-8 and CCL2. The levels
of these and other innate soluble factors decreased with time on
ATT, whereas markers of activation of adaptive immune
responses significantly increased. We have previously shown for
the same cohort of patients described here, that time from ATT to
ART initiation was strongly associated with the occurrence of TB-
IRIS, even after adjustment for several confounding factors, such
as CD4+ T-cell counts and HIV viral load [30]. Because the
majority of the IRIS patients were on ATT for a shorter period
compared with non-IRIS controls, we speculate that the activated
innate immune signature in these individuals may set the stage for
paradoxical TB-IRIS upon ART initiation. More importantly, we
describe that multiple soluble parameters measured in TB-IRIS
patients during the event were not only increased in expression but
also displayed strong positive correlations with each other,
suggesting they belong to common activation pathways.
To our knowledge, this is the first study that formally describes
monocyte subsets in an at-risk TB-HIV co-infected population and
demonstrates associations between activation of these cellular
subsets and TB-IRIS. Our results clearly show that the compo-
sition of monocyte subsets is significantly different between IRIS
and non-IRIS patients, even before ART initiation. The striking
finding that CD14++CD162 and CD14+CD16+ monocytes are
increased, whereas CD14dimCD16+ cells are dramatically de-
creased, in IRIS patients before ART initiation implies that the
relative distribution of monocyte subsets may be an important
predictor of IRIS. In addition, these results indicate that CD14+
monocytes or tissue myeloid cells derived from circulating
monocytes might be the source of several of the inflammatory
cytokines detected in plasma. The function of the different
monocyte subsets in producing pro- or anti-inflammatory cyto-
kines is controversial and has been variably reported in past
studies, depending on the experimental design and inflammatory
setting. Studies assessing sorted monocytes stimulated with
different Toll-like receptor (TLR) ligands show that
CD14dimCD16+ cells are more prone to producing TNF-a,
whereas CD14+CD16+ cells are a major source of IL-10 [44,45].
More recently, CD14dimCD16+ cells were shown to exhibit
patrolling characteristics, with a weak ability for phagocytosis
and a limited capacity to produce reactive oxygen species and
cytokines when stimulated with bacterial TLR agonists but high
amounts of TNF-a and IL-1b upon stimulation with viral ligands
or nucleic acids [46]. These findings suggest that monocyte subsets
cannot be categorized merely as pro- or anti-inflammatory and
that their effector functions may depend on the activation pathway
and immune microenvironment. Our study reveals that among the
different types of monocytes, the CD14++CD162 subset is the key
monocyte population producing inflammatory cytokines and,
upon ART initiation, has a clearly differentiated trajectory,
expanding in TB-IRIS patients and proportionally decreasing in
non-IRIS patients.
Macrophages derived from CD14++CD162 monocytes have
been shown to be more permissive to Mtb growth in vitro than
those derived from the CD14dimCD16+ subset [47], due to
increased c-maf expression. It is plausible that increased numbers
of CD14++CD162 monocytes of TB-HIV co-infected individuals
with very low CD4+ T-cell counts (and, thus, with reduced
capacity to provide co-stimulatory signals for antigen presenting
cells) generate macrophages that are more permissive to Mtb
infection and replication. When HIV-mediated immunosuppres-
sion is decreased upon ART initiation and antigen-specific CD4+
T-cells rapidly reconstitute, this may create a burst of T-cell help,
with large numbers of infected macrophages now becoming fully
activated simultaneously in individuals developing paradoxical
TB-IRIS. This would result in a massive production of pro-
inflammatory mediators, which contributes to IRIS immunopa-
thology. We have proposed this hypothesis previously, based on
observations from a murine model of mycobacterial IRIS in which
similar changes in the same monocyte subsets are observed
[17,27,28]. A pathogenic role of neutrophils was not supported by
our data but was not studied exhaustively and should be further
investigated.
In the current study, the percentage of circulating
CD14++CD162 monocytes, but not other subsets, was significantly
correlated with several pro-inflammatory cytokines before and
after ART initiation, reinforcing this hypothesis. In addition, we
have also demonstrated here that CD14++CD162 monocytes from
HIV+ patients with suppressed viral replication are capable of
producing larger amounts of IL-6 and TNF-a than at pre-ART
upon stimulation with increasing doses of Mtb. Spontaneous direct
ex vivo cytokine production was also higher pre-ART in TB-IRIS
patients. These results may lead us to speculate that once HIV+
individuals with higher mycobacterial antigen loads suppress HIV
replication, they become highly responsive to Mtb stimulation,
which results in the production of pro-inflammatory cytokines that
contribute to the activation of inflammatory pathways and the
resultant immunopathology of TB-IRIS. The lack of differences in
direct spontaneous cytokine production of monocytes from TB-
IRIS patients at the IRIS time point may represent trafficking and
maturation into tissue macrophages or myeloid dendritic cells, a
hypothesis that should be further investigated. Understanding the
key determinants from the innate immune system, and myeloid
cells more specifically, that play a fundamental role in TB-IRIS
can help develop better strategies for the prediction, clinical
management and pharmacologic targeting of this important
complication of ART.
Materials and Methods
Description of the patients from the South Indian cohort
The Indian TB-IRIS cohort study was nested within a
randomized controlled trial (NCT 933790) at the National
Institute for Research in Tuberculosis (NIRT), Chennai, enrolling
HIV infected patients with newly diagnosed sputum culture-
confirmed pulmonary TB, as previously reported [30]. The parent
randomized controlled clinical trial (ongoing at the time of this
report) is comparing daily vs. intermittent anti-TB therapeutic
regimens in HIV infected patients with pulmonary TB [30].
Eligible participants were above 18 years of age, HIV infected, and
initiating ART with pulmonary TB confirmed by sputum culture
positive for rifampicin-sensitive Mycobacterium tuberculosis (Mtb).
Clinical evaluations and blood collections were performed at
baseline (pre-ART), at the time of IRIS event (between weeks 2–6
of ART) or after 6 weeks of ART in the non-IRIS group, and after
6 months of ART in both groups. Mycobacterial loads in sputum
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cultures were assessed as described elsewhere [30]. Patients were
hospitalized for ART initiation and were discharged within two
weeks. In this cohort, 48 individuals were enrolled and 26 (54%)
developed IRIS during the study. IRIS events occurred at a
median of 11 days (interquartile range, IQR: 7–16) after ART
initiation. Patients who experienced IRIS were similar to those
with uneventful follow-up (designated as controls who were also
HIV-TB co-infected but did not develop IRIS) with regard to age,
gender, body weight, and hepatic transaminase levels. In addition,
CD4+ T-cell counts dramatically increased and plasma HIV viral
load significantly decreased in all patients, and there was no clear
difference in the magnitude of changes in these variables after the
initiation of ART between patients who developed IRIS and those
who did not [30]. The detailed clinical, laboratory, and
microbiologic description of the study participants has been
previously reported by our group [30].
Description of the patients from the South African cohort
The South African cohort originated from a prospective
observational study of hospitalized patients with HIV-associated
TB conducted at Brooklyn Chest Hospital (Cape Town) between
April 2009 and February 2011, as previously described [31,32].
Inpatients at this hospital are transferred from other hospitals or
referring TB clinics with an established diagnosis of severe TB and
prescribed anti-TB treatment. In the parent study, HIV-TB
patients were enrolled and followed for 12 weeks following ART
initiation. Their median CD4 count was 55 cells/mL (IQR = 31–
106) and median time from starting TB treatment to ART was 36
days (IQR = 27–57). A total of 112 patients were recruited, and 47
individuals (42%) developed paradoxical TB-IRIS, fulfilling
INSHI case definitions [8] after a median of 12 days on ART
(range 4–49). Collection of blood samples was performed at the
study baseline (pre-ART) and at week 2 after ART initiation in
both patients who developed IRIS and in those who did not during
the follow up. Only ART-naı¨ve patients were included in the
immunological analyses (52 non-IRIS and 44 IRIS patients). A
detailed description of the patients used in the immunological
analyses is shown in Table S3.
Description of the patients from the North American
cohort
Paired cryopreserved PBMC samples from eight HIV-infected
individuals non-infected with Mycobacterium tuberculosis prior to
ART initiation (pre-ART) and after 8 weeks of ART initiation
when patients achieved virological suppression were analyzed
using intracellular cytokine assays. Patients had a median age of 32
years (IQR: 25–43 years), and 56% were female. Median pre-
ART CD4+ T cell count was 32 cells/mL (IQR: 10–53 cells/mL),
and median log10 HIV RNA level was 5.00 copies/mL (IQR:
4.46–5.27 copies/mL). At week 8 post-ART initiation (for 2
patients it was closer to week 12), CD4+ T-cell count was 82 cells/
mL (IQR: 61–147 cells/mL), and median log10 HIV RNA level was
1.7 copies/mL (IQR: 1.7–1.8 copies/mL); these variables were
significantly different from pre-ART values (P = 0.039 and
P = 0.008, respectively).
Ethics statement
All clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki. Written
informed consent was obtained from all participants before
enrolling into the sub-studies. The Indian study was approved
by the Scientific Advisory Committee and Institutional Ethics
Committee of the National Institute for Research in Tuberculosis
(Chennai) and is registered on Clinicaltrials.gov (NCT 933790).
The South African study was approved by the University of Cape
Town Faculty of Health Sciences Human Research Ethics
Committee (HREC 049/2009). The North American study was
approved by the NIAID Ethics committee, and the study is
registered in Clinicaltrials.gov (NCT #00286767).
Plasma biomarker measurements
Concentrations of IL-1b, IL-1Ra, IL-6, IL-8, IL-10, IL-12p40,
IL-12p70, IL-15, CCL2, CCL3, CCL4, CCL5, CCL11,
CXCL10, IFN-c, TNF-a, TGF-b, platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF) (Bio-Plex, Bio-
Rad, Hercules, CA), C-reactive protein (CRP) (eBioscience, San
Diego, CA), soluble (s) CD14, sCD163, soluble tissue factor (sTF)
(R&D Systems, Minneapolis, MN) and intestinal fatty acid binding
protein (I-FABP) (Hycult Biotech, The Netherlands) were assessed
in cryopreserved plasma samples maintained at 280uC from
patients in the Indian cohort. A smaller panel of biomarkers
containing IL-6, IL-8, IL-10, IL-12p40, IFN-c, TNF-a, CCL3,
CCL4, CXCL10, sCD14, sCD163 and sTF was investigated in
the South African cohort due to limitations in available plasma
volume.
Flow cytometry
The immunophenotyping of monocytes and dendritic cells (DC)
was performed in whole blood collected in heparinized vacuum
tubes. For ex vivo phenotyping, aliquots of 250 mL blood were
stained with five panels of antibodies prepared in PBS 1% BSA for
1 h at room temperature (RT) to characterize the myeloid
populations. The panels with antibody clones and fluorochromes
as well as the gating strategies are listed in Figure S1. Antibodies
were from eBioscience (San Diego, CA), Biolegend (San Diego,
CA), BD Biosciences (San Jose, CA) and Life Technologies
(Carlsbad, CA). Data from the Indian cohort were acquired on a
BD FACS Canto II flow cytometer (BD Biosciences) and from the
North American cohort were acquired on a BD LSR II flow
cytometer (BD Biosciences). Three major monocyte subsets are
considered for analysis based on CD14 and CD16 surface
expression: classical/inflammatory (CD14++CD162), intermediate
(CD14+CD16+) and patrolling (CD14dimCD16+) monocytes. Data
on monocyte subsets are displayed as percent of circulating
mononuclear myeloid cells, defined in this study as HLA-DR+
Dump2 (CD22CD32CD192CD202CD562) cells in the blood.
All compensation and gating analyses were performed using
FlowJo 9.5.3 (TreeStar, Ashland, OR).
Intracellular cytokine assay
Frozen peripheral blood mononuclear cells (PBMC) were
thawed and resuspended in RPMI-1640 media supplemented
with 10% human AB serum, plated at 106 cells/well in round
bottom 96-well plates, and stimulated for 6 h with different
concentrations of irradiated Mtb (0–100 mg/mL) in the presence
of brefeldin-A at 37uC in 5% CO2. Cells were washed with PBS
and incubated with Live/dead fixable blue dead cell stain (Life
Technologies) for 20 min at RT, and then washed and stained
with antibodies for surface markers. Cells were then fixed and
permeabilized (Foxp3/Transcription Factor Staining Buffer Set,
eBioscience) for 1 h at RT. After permeabilization, cells were
stained for intracellular IL-6 and TNF-a (1 h at RT).
Spontaneous cytokine production by leukocytes in whole blood
from TB-HIV co-infected patients was also assessed by incuba-
ting500 mL of fresh heparinized whole blood aliquots in polypro-
pylene tubes at 37uC in 5% CO2, for 6 hours in the presence of
Brefeldin A 5 mg/mL (BD Biosciences). Cells were fixed with 4%
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formaldehyde (Sigma Aldrich) and red cells lysed with BD FACS
Lysing Solution (BD Biosciences). Cells were frozen in PBS 10%
DMSO at 280uC and then at liquid nitrogen until all patients
from the clinical study were recruited. All samples were thawed,
re-suspended in FACS buffer and stained for surface markers.
Cells were then permeabilized with eBioscience Permeabilization
Buffer (eBiosciences) and stained for intracellular cytokines (IL-1b,
IL-6 and TNF- a) and acquired in the flow cytometer.
Network analysis
The inferential networks were generated from Spearman
correlation matrices containing values of each biomarker mea-
sured in the plasma samples and blood cell counts (neutrophils and
monocytes). The values were inputted in JMP 10.0 software (SAS,
Cary, NC, USA). Each mediator is selected as a target, and the
software performs a search within the other mediators for those
that are correlated, with the target calculating a correlation matrix
using Spearman rank tests. As a result, the features related to the
selected target are linked. The links shown in the networks
represent statistically significant Spearman rank correlations (P,
0.05). In order to analyze the structure of the biomarker networks,
the network density was calculated, which is, in the context of this
study, the ratio of the number of edges inferred in the network
over the total number of possible edges between all pairs of nodes
[48]. The density measure is defined as follows: density = L/(N (N-
1)/2), in which L is the number of observed edges (i.e., Spearman
correlations with P,0.05) and N is the total number of the nodes
in the network. The density is normalized, ranging between 0 (no
edges in the network) and 1 (all possible edges presents). The
number of statistically significant correlations was compared
between the IRIS and non-IRIS groups at the different time
points using the permutation test. The same test was used to
compare the changes in the number of significant correlations in
the networks from week 0 to week 6/IRIS event within the two
clinical groups. Graphics for the network analysis were customized
using the Ingenuity Systems Pathway Analysis software (Ingenuity
Systems, Redwood City, CA, USA) and Adobe Illustrator (Adobe
Systems Inc.).
Data analysis
Median values with IQR or frequencies of variables were
compared using the Mann-Whitney test (when two groups were
compared) or the Kruskal-Wallis test with Dunn’s multiple
comparisons ad hoc analysis (when three groups were compared).
Fisher’s exact test or Chi-square tests were used to compare two or
three groups, respectively, when data were displayed as percentages.
Paired changes from before ART initiation to week 6 or the time of
IRIS were compared using the Wilcoxon matched-pairs test. Using
JMP 10.0 software, geometric mean values (log10) for each marker
measured at week 0 and week 6 (Indian cohort) or week 2 (in South
African cohort) were calculated for the entire study population. To
assess the overall pattern of expression of these markers in each
clinical group and time point, heat maps were built using variation
from geometric mean values calculated for each candidate
biomarker. A hierarchical cluster analysis using the Ward’s method
was employed to reveal the patterns of expression in plasma. The
analyses were first performed in the Indian cohort and then
repeated in the South African cohort for validation. The databank
from South Africa contained a reduced number of biomarkers
compared to India, and there was no pre-selection of markers based
on the Indian cohort data. The relative risk (RR) of IRIS per
standard deviation increase in the percentage of different monocyte
subsets at week 0 (pre-ART) after log10 transformation was also
calculated. RRs were adjusted for baseline age, gender, days to
ART initiation, plasma HIV RNA levels and CD4+ T-cell count.
Throughout the text, a statistically significant difference was defined
as a P value,0.05. The statistical analyses were performed using
GraphPad Prism 6.0 (GraphPad Software Inc., USA), STATA 9.0
(StataCorp, TX, USA), and JMP 10.0 software.
Supporting Information
Data file S1 Correlations from South Indian Cohort.
(XLSX)
Data file S2 Correlations from South African Cohort.
(XLSX)
Figure S1 Gating strategy used to assess monocytes. (A)
Antibody panels used to assess phenotype of monocytes and
dendritic cells, as well as intracellular cytokine production by
monocytes. (B) Gating strategy used to evaluate monocytes subsets
in whole blood.
(TIF)
Figure S2 Analysis of network densities of inflammato-
ry biomarkers from TB-HIV co-infected patients from
the Indian and South African cohorts. Bars represent the
network densities (calculated as described in Methods); symbols,
and whiskers represent median values and interquartile ranges for
plasma HIV viremia (left panels) or CD4+ T-cell counts from
patients recruited in the Indian (A) or South African (B) cohorts.
Plasma HIV-RNA and CD4+ T-cell counts were compared
between patients at week 0 (pre-ART) and at week 2 after ART
initiation using the Wilcoxon matched-pairs test (*** P,0.001).
Differences between the network intensities were compared
between week 0 and weeks 2–6/time of IRIS (# denotes P,
0.05) or between IRIS and non-IRIS groups at each study time
point ({ denotes P,0.05) using permutation tests.
(TIF)
Figure S3 Expansion of circulating CD14++CD162
monocytes is a hallmark of TB-IRIS in South India. (A)
Percentage of mononuclear myeloid cells (HLA-
DR+CD22CD32CD192CD202CD562) within total circulating
leukocytes was compared at week 0 (pre-ART) and at weeks 6 or at
the time of IRIS after ART initiation between TB-HIV co-
infected patients that developed paradoxical TB-IRIS (n = 26) and
those who did not (n = 22). Data were analyzed using the Mann-
Whitney test or Wilcoxon matched-pairs test for analyses between
and within study groups. (B) Pie charts (right panel) show median
percentage of different circulating myeloid cell subsets at week 0
(pre-ART) and week 6 or at the time of IRIS after ART initiation.
Bar graphs (right panel) show changes in percentage of the
different myeloid cell subsets between week 6 and week 0 for IRIS
vs. non-IRIS patients. Delta variations for each cellular subset
were compared between IRIS and non-IRIS groups using the
Mann-Whitney test. * P,0.05, ** P,0.01, *** P,0.001.
(TIF)
Figure S4 Intracellular cytokine staining of circulating
monocytes and neutrophils from TB-HIV infected
patients. (A) Refined gating strategy to identify neutrophils and
monocytes used in the South Indian cohort. (B) Representative
plots with median and IQR values of monocytes spontaneously
producing IL-1b, IL-6 or TNF-a are shown for IRIS (n = 17) and
non-IRIS patients (n = 15) at IRIS event or week 6, respectively.
Frequencies of cytokine producing cells were compared between
the groups using Mann-Whitney test.
(TIF)
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Table S1 Distribution of plasma biomarkers and cell
counts in the Indian Cohort.
(DOCX)
Table S2 Distribution of plasma biomarkers and cell
counts in the South African Cohort.
(DOCX)
Table S3 Baseline characteristics of the South African
patients.
(DOCX)
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